Like a few other individuals on this board, I agree with

New Post Public Reply Private Reply Replies (2) Message Board
MGK_2
799
Like a few other individuals on this board, I agree with putting Pestell in the camp of 13D. He was their largest contributor. Without him, there was no 13D by sheer quantity of his holdings.

Really, when someone was at least the "backer" of such a parasitical group like 13D, how can he be found not to be just that.

Using CYDY for his prostate test, being Chief Medical Officer, sucking the life out of a trial by questioning LL's safety profile?, the 8.3 million shares and now another 7 million to boot? He has literally sucked the blood from his host organism. Does all this not prove his parasitical feeding on CytoDyn, using his CCR5 knowledge as his free pass to feed on what his heart desires?

I align him with Amarex. I only have a suspicion, but the backers of the work which was committed against our HIV trial, to mutilate the BLA for HIV, had to be in collusion with Amarex to accomplish this deed, and it was achieved when 13D had not yet quite made their revelation. Had the BLA been received and Filed by the FDA, LL would be approved today for HIV and Covid 19 as well. The needless death of hundreds of thousands could have been prevented had Amarex done its job. Had, BP, and 13D not interfered with our trials.

There never would have been a 13D uprising or Amarex Arbitration for that matter. Nader would still be in charge. Covid would have been minimized.

Now, we have no Nader, we have the re-emergence of a parasite, the reminders of a 13D renaissance and how Amarex caused all of this to go down.

A curve ball thrown to the shareholders. CytoDyn negotiates with 13D? What would be the benefit? Obviously... there must be some great benefit. Right? given the magnitude of the award. Why did we not shut him down completely, but opted to settle the case even a week early, in the way that we did?

Was it Karen Brunke who liked his CCR5 understanding? Does she feel he would help her figure out new LL indications? Were they looking to free up a board position and knew Jordan Naydenov would leave with that settlement? There must have been reasons which made it worth far more than that.

Who does he know? What corporations is he affiliated with? In what capacity? What was discussed prior to the decision to make this grand settlement? What was implied in the statement, "Dr. Pestell and the Company are also exploring ways in which Dr. Pestell can reengage with the Company to help realize leronlimab’s full potential in oncology. CytoDyn regrets Dr. Pestell’s departure from the Company and the subsequent public statements made by its former CEO about Dr. Pestell."

What, He is not the parasite he once was? He only had it out for Nader and now, since Nader is gone, he will play nice?

Does he have any part of the collusion which had to have happened in Amarex? Is it too far fetched, to consider that he, with friends in high places, in the seats of the decision makers of Big Pharma, those that give the yea or nay on the treachery, the debauchery, in discussions, making recommendation, offering of advice. Yet, his name remains clean, devoid of any tarnish or flaw, polished with painstaking care to maintain it as flawless.

What is the value of the Amarex destruction? Minimum $13 Billion induced by the 13D. How would Sidley Austin have not advised against such a settlement if he were implicated in Amarex? Clearly, we expect more out of him than $13 Billion.

What if the opposite were true? What if he will now yield the truth to Sidley Austin on the BLA and Amarex? I wrote this in Taking a Look Ahead,

https://www.reddit.com/r/LeronLimab_Times/com...;context=3

"None are immune. All have deep pockets. All will be found out and discovered. The implications of which are enormous. CytoDyn swallows whole the elephant in the room. Negotiations? There will be nothing left to negotiate for, not even half an ear. No crumbs under the table. And Amarex will not be the only one consumed."

I also wrote, "CytoDyn needs to remain vigilant. Be careful of the covenants you sign CytoDyn. Leronlimab may not be breached. That must be forbidden. There can be no access to its assembly or manufacturing. There can be no understanding to its formula. There can be no decoding.

If for whatever reason, this is actually breached. all contracts / partnerships cease at once and CytoDyn goes it alone again. That must be written in every contract. Whoever would have breached this will be fighting with their best foot forward to again destroy CytoDyn."

Richard Pestell will not be CytoDyn's new CEO. He will however be CytoDyn's liaison in winning combination therapy partnerships with multiple Big Pharmaceuticals to broaden, strengthen and fortify the indications of their concluding monotherapy drugs for new use as combination therapy with Leronlimab. He will make amends and reap far greater rewards from his host in its rise than he ever has in its fall.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Advenica: Rising Star in Secure File Transfer Market

Updated Category News Views 1

Advenica's Ascent in Secure File Transfer The cybersecurity world never sleeps, and with the rapid pace of digital threats, it's no surprise that secure file transfer solutions are becoming hotter commodities than coffee pots on Wall Street. Advenica, a name that might not ring a bell for everyone, has emerged as an 'Emerging Leader' in MarketsandMarkets' latest...

Continue Reading
KuCoin's KCUSD Tackles Stablecoin Idle Capital Problem

Updated Category News Views 1

KuCoin's Bold Move with KCUSD Folks, the cat's outta the bag with KuCoin's latest maneuver—introducing KCUSD. At first glance, it seems like they're just introducing another fancy stablecoin product, but peel the onion and there's more to it. We're talking about shaking up how stablecoins sit tight doing nada in the crypto world. KCUSD is out to make those idle balances...

Continue Reading
Europe's Largest Carbon Capture Facility Launches

Updated Category News Views 2

A New Chapter in Industrial Decarbonization Today's not just your average ribbon-cutting ceremony; it's a landmark turn in our journey toward a cleaner Europe. Yara's Sluiskil plant in the Netherlands just fired up Europe's biggest carbon capture facility, marking a crucial pivot point in industrial decarbonization. We're talking about capturing a staggering 800,000 tons...

Continue Reading
Sungrow's MGTL Series: A Game-Changer in Solar Tech

Updated Category News Views 2

Smarter Energy Systems Are Here Gone are the days when solar inverters were just clunky bits of tech you threw on a roof. Sungrow's latest MGTL Series, revealed in Da Nang, marks a revolutionary step for Southeast Asia, Africa, Latin America, and beyond. They're not just talking the talk—they're bringing real innovation to the table. Why the MGTL Series Stands Out Look,...

Continue Reading
Snack Bars Market to Hit $32.66B by 2031: Growth and Challenges

Updated Category News Views 2

Snack Bars Navigate a Transforming Market There's a headwind in the snack bars market as it looks to lift off from $21.94 billion and land at $32.66 billion by 2031. That's a solid climb at an 8.28% CAGR. What's fueling this leap? A desire for convenient, portable nutrition that's squeezing into every nook of modern life—from the gym to the car, to your kid's lunchbox....

Continue Reading
Michigan Roof Inspections: Seasonal Insights That Count

Updated Category News Views 3

Weather's Wrath and the Michigan Roof Here's the deal: Michigan doesn't mess around when it comes to weather. We're talking harsh winters with piles of snow, followed by muggy summers that toss storms like they're confetti. Keeping that roof in top shape isn't just some luxury; it’s a downright necessity. Gut-punch reality? Many ignore it until it's too late. That's...

Continue Reading
53% of European Telecom Users Eye Provider Switch

Updated Category News Views 3

Change Is Brewing in Europe's Telecom Markets Seems like Europe's telco scene is simmering. Over half of consumers in major European markets are giving their mobile providers the side-eye, ready to jump ship. That's putting the heat on operators who once banked on loyalty programs to keep their customer base intact. Diverse Loyalty Challenges Across Europe What's...

Continue Reading
Overpricing in Atlanta Luxury Real Estate: Risks & Rewards

Updated Category News Views 4

When Pricing Sends the Wrong Message Jump into the high stakes poker game of Atlanta's luxury real estate, and you'll find that pricing strategy is your make-or-break move. Jud Whitlock, a seasoned veteran over at Atlanta Fine Homes/Sotheby's International Realty, lays it all down: in this digital age, pricing too high is akin to waving a red flag at savvy buyers armed...

Continue Reading
Thermoplastic Polyimide: A $0.86 Billion Market by 2032

Updated Category News Views 1

It's not often you get hyped about a compound with a name like 'thermoplastic polyimide,' but hold your horses—this isn't just any chemical. If you're watching markets with a sharp eye, you’ll see this thing estimated at $0.56 billion in 2026, gunning for a hefty $0.86 billion by 2032. We're talking about a solid 7.4% CAGR ride here folks, according to new data from...

Continue Reading
DNOW Faces Class Action: Proxy Missteps Under Fire

Updated Category News Views 1

DNOW's Rough Patch: Investors, Beware Here's a tangled mess for you: DNOW Inc., a name that should've been cruising post-merger, now finds itself smack in the middle of a class action lawsuit. Blame it on some botched acquisition moves with MRC Global Inc. The suits claim DNOW's management may have played fast and loose with the truth during their big merger spiel. When...

Continue Reading

Top 5 Most Recently Viewed Articles

Semler Scientific, Inc. Faces Investor Legal Action Opportunities

Updated Category News Views 128

Investing in Semler Scientific, Inc. (NASDAQ: SMLR) Investors in Semler Scientific, Inc. have found themselves at a crucial crossroads as the company faces significant allegations regarding securities fraud. This situation presents an opportunity for investors to consider what steps they can take to safeguard their investments and potentially recover losses incurred....

Continue Reading
Flywire Corporation Set to Showcase at Major Tech Conference

Updated Category News Views 129

Flywire Corporation to Attend Major Investor Conference Flywire Corporation (NASDAQ: FLYW) has recently announced its participation in the highly anticipated UBS Global Tech and AI Conference. The event will take place in Phoenix, Arizona. The Company's session is scheduled for 7:35 am MST, where they will engage in an insightful fireside chat. Webcast and Replay Details...

Continue Reading
Nuance Pharma Boosts Bentrio Availability Across Asia Regions

Updated Category News Views 145

Nuance Pharma Expands Distribution for Bentrio Nasal Spray Nuance Pharma is making significant strides by enhancing its exclusive license and distribution agreement with Altamira Medica Ltd. This updated contract now extends coverage to seven additional countries in East and Southeast Asia. The announcement was made by Altamira Therapeutics Ltd. (NASDAQ: CYTO), the parent...

Continue Reading
Investigation on Crocs Holdings: Your Rights as an Investor

Updated Category News Views 128

Investor Alert: Ongoing Investigation into Crocs Holdings Faruqi & Faruqi, LLP is actively investigating the financial practices of Crocs, Inc. (NASDAQ: CROX) amidst mounting concerns over the company's revenue reporting and overall operations. For investors holding substantial stakes in Crocs, understanding the implications of this investigation is crucial for protecting...

Continue Reading
NovaBridge's New Leaders Accelerate VIS-101 Development

Updated Category News Views 221

Strategic Appointments Propel VIS-101 Forward In an exciting development for VIS-101, NovaBridge Biosciences has appointed two distinguished leaders in ophthalmology, Cadmus C. Rich, MD, MBA, as Chief Medical Officer and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board. Their expertise will significantly enhance the clinical development of this...

Continue Reading